156 related articles for article (PubMed ID: 11792412)
1. High serum soluble CD44 is correlated with a poor outcome of aggressive non-Hodgkin's lymphoma.
Niitsu N; Iijima K
Leuk Res; 2002 Mar; 26(3):241-8. PubMed ID: 11792412
[TBL] [Abstract][Full Text] [Related]
2. Elevated serum levels of soluble CD44 variant 6 are correlated with shorter survival in aggressive non-Hodgkin's lymphoma.
Sasaki K; Niitsu N
Eur J Haematol; 2000 Sep; 65(3):195-202. PubMed ID: 11007056
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of serum CD44, intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 levels in patients with indolent non-Hodgkin lymphomas.
Shah N; Cabanillas F; McIntyre B; Feng L; McLaughlin P; Rodriguez MA; Romaguera J; Younes A; Hagemeister FB; Kwak L; Fayad L
Leuk Lymphoma; 2012 Jan; 53(1):50-6. PubMed ID: 21895545
[TBL] [Abstract][Full Text] [Related]
4. A high serum-soluble interleukin-2 receptor level is associated with a poor outcome of aggressive non-Hodgkin's lymphoma.
Niitsu N; Iijima K; Chizuka A
Eur J Haematol; 2001 Jan; 66(1):24-30. PubMed ID: 11168504
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of soluble CD44 in patients with breast and colorectal carcinomas and non-Hodgkin's lymphoma.
Lockhart MS; Waldner C; Mongini C; Gravisaco MJ; Casanova S; Alvarez E; Hajos S
Oncol Rep; 1999; 6(5):1129-33. PubMed ID: 10425314
[TBL] [Abstract][Full Text] [Related]
6. Serum levels and differential expression of CD44 in childhood leukemia and malignant lymphoma: correlation with prognostic criteria and survival.
Taçyildiz N; Cavdar AO; Yavuz G; Gözdaşoglu S; Unal E; Ertem U; Duru F; Ikinciogullari A; Babacan E; Kuzu I; Cin S
Pediatr Int; 2001 Aug; 43(4):354-60. PubMed ID: 11472578
[TBL] [Abstract][Full Text] [Related]
7. Elevated serum levels of soluble CD44 can identify a subgroup of patients with early B-cell chronic lymphocytic leukemia who are at high risk of disease progression.
Molica S; Vitelli G; Levato D; Giannarelli D; Gandolfo GM
Cancer; 2001 Aug; 92(4):713-9. PubMed ID: 11550139
[TBL] [Abstract][Full Text] [Related]
8. Elevated serum CD44 level is associated with unfavorable outcome in non-Hodgkin's lymphoma.
Ristamäki R; Joensuu H; Lappalainen K; Teerenhovi L; Jalkanen S
Blood; 1997 Nov; 90(10):4039-45. PubMed ID: 9354673
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of some biochemical markers as prognostic factors in malignant lymphoma.
Khalifa KA; Alkilani AA; Ismail H; Soliman MA
J Egypt Natl Canc Inst; 2008 Mar; 20(1):47-54. PubMed ID: 19847281
[TBL] [Abstract][Full Text] [Related]
10. Serum-soluble tumor necrosis factor receptor 2 (sTNF-R2) level determines clinical outcome in patients with aggressive non-Hodgkin's lymphoma.
Goto N; Tsurumi H; Takemura M; Hara T; Sawada M; Kasahara S; Kanemura N; Yamada T; Shimizu M; Takahashi T; Tomita E; Seishima M; Takami T; Moriwaki H
Eur J Haematol; 2006 Sep; 77(3):217-25. PubMed ID: 16856931
[TBL] [Abstract][Full Text] [Related]
11. Tumor necrosis factor ligand-receptor system can predict treatment outcome in lymphoma patients.
Warzocha K; Salles G; Bienvenu J; Bastion Y; Dumontet C; Renard N; Neidhardt-Berard EM; Coiffier B
J Clin Oncol; 1997 Feb; 15(2):499-508. PubMed ID: 9053471
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the Revised European-American Lymphoma classification confirms the clinical relevance of immunophenotype in 560 cases of aggressive non-Hodgkin's lymphoma.
Melnyk A; Rodriguez A; Pugh WC; Cabannillas F
Blood; 1997 Jun; 89(12):4514-20. PubMed ID: 9192775
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of the immunophenotype versus the International Prognostic Index in aggressive non-Hodgkin's lymphoma.
Intragumtornchai T; Rotnakkarin P; Sutcharitchan P; Wannagrairoj P
Clin Lymphoma; 2003 Jun; 4(1):52-5. PubMed ID: 12837156
[TBL] [Abstract][Full Text] [Related]
14. Non-Hodgkin's lymphoma after primary Hodgkin's disease in the German Hodgkin's Lymphoma Study Group: incidence, treatment, and prognosis.
Rueffer U; Josting A; Franklin J; May M; Sieber M; Breuer K; Engert A; Diehl V;
J Clin Oncol; 2001 Apr; 19(7):2026-32. PubMed ID: 11310450
[TBL] [Abstract][Full Text] [Related]
15. Serum CD44 levels preceding the diagnosis of non-Hodgkin's lymphoma.
Mäenpää H; Ristamäki R; Virtamo J; Franssila K; Albanes D; Joensuu H
Leuk Lymphoma; 2000 May; 37(5-6):585-92. PubMed ID: 11042519
[TBL] [Abstract][Full Text] [Related]
16. Clinical significance of circulating CD44 in non-Hodgkin's lymphoma.
Ristamäki R; Joensuu H; Hagberg H; Kalkner KM; Jalkanen S
Int J Cancer; 1998 Jun; 79(3):221-5. PubMed ID: 9645341
[TBL] [Abstract][Full Text] [Related]
17. Serum soluble CD44 in pediatric patients with acute leukemia.
Takeuchi M; Tanizawa A; Fukumoto Y; Kikawa Y; Mayumi M
J Pediatr Hematol Oncol; 1999; 21(5):384-8. PubMed ID: 10524451
[TBL] [Abstract][Full Text] [Related]
18. [Prognosis of primary non-Hodgkin's lymphoma of the breast].
Guo HY; Zhao XM; Cao JN; Hu XC; Yin JL; Hong XN; Li J
Zhonghua Zhong Liu Za Zhi; 2008 Mar; 30(3):200-2. PubMed ID: 18756936
[TBL] [Abstract][Full Text] [Related]
19. Prognostic implications of the differentiation inhibitory factor nm23-H1 protein in the plasma of aggressive non-Hodgkin's lymphoma.
Niitsu N; Okabe-Kado J; Kasukabe T; Yamamoto-Yamaguchi Y; Umeda M; Honma Y
Blood; 1999 Nov; 94(10):3541-50. PubMed ID: 10552965
[TBL] [Abstract][Full Text] [Related]
20. Serum CD44 in non-Hodgkin's lymphoma.
Ristamäki R; Joensuu H; Jalkanen S
Leuk Lymphoma; 1999 May; 33(5-6):433-40. PubMed ID: 10342571
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
